Contact MENU

News

Showing posts for — Author: kioradev

06.22.18

EyeGate Addresses Final FDA Action Item with Submission of IDE Amendment for Ocular Bandage Gel

Responses to the last of four outstanding action items submitted; Potential to start clinical study in the Third Quarter of 2018 WALTHAM, Mass., June 22, 2018 — EyeGate Pharmaceuticals, Inc....
Read more
05.30.18

EyeGate Files Supplement to Investigational Device Exemption to Commence Study in Punctate Epitheliopathy using the EyeGate Ocular Bandage Gel

Continued Expansion of the EyeGate OBG Franchise WALTHAM, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two...
Read more
05.22.18

EyeGate technology featured in a Journal of Cataract and Refractive Surgery article

Hyaluronic acid (HA) is a key molecule identified for its wound-healing capacity in dermal and ocular injuries, however it is quickly degraded and cleared by the body limiting its effectiveness...
Read more
05.22.18

ScienceDirect: “Treatment of corneal chemical alkali burns with a crosslinked hyaluronic acid film”

The severe and caustic nature of alkali chemical burns affecting the eye often leads to permanent ocular injury and resulting vision loss.  Treatment options are limited, particularly as the topical...
Read more
05.22.18

Dr. Paul Karpecki’s article in Ocular Surface Review, “HA: No Laughing Matter”

In this article, Dr. Paul Karpecki takes a closer look at the various hyaluronic acid (HA)-based products optometrists currently have access to and the future role of HA-based therapies in...
Read more
05.22.18

EyeGate Poster on Crosslinked Hyaluronic Acid (CMHA-S), Ocular Bandage Gel-based Delivery of Small Molecules

Corneal ulcers are an ocular emergency and a leading cause of blindness globally. The treatment regimen usually requires hourly (or in some cases, even more frequent) round-the-clock administration of topical...
Read more
05.22.18

EyeGate Addresses Majority of FDA’s Action Items with Submission of Investigational Device Exemption Amendment for Ocular Bandage Gel

Responses to three of the four outstanding action items submitted; Response to Fourth action item Expected in the Second Quarter of 2018 with Potential to start clinical study in the...
Read more
05.16.18

EyeGate Pharmaceuticals Announces New Board Member, Steven Boyd

WALTHAM, Mass., May 16, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders...
Read more

Stay up to date with the latest company news

Sign Up